A novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation

Area of Science:

• Molecular Biology
• Cell Biology
• Biochemistry

Background:

• Diaryl trifluorothiazoline compound 1a (fluorizoline) is a novel small molecule inducing p53-independent apoptosis in tumor cells.
• Fluorizoline directly binds to prohibitin 1 and 2 (PHBs), proteins regulating cellular processes including apoptosis.

Purpose of the Study:

• To elucidate the mechanism of fluorizoline-induced apoptosis.
• To determine the role of prohibitin proteins (PHBs) in fluorizoline's apoptotic effects.
• To confirm the involvement of the intrinsic apoptosis pathway.

Main Methods:

• Cellular apoptosis assays in various tumor cell lines.
• Prohibitin protein (PHB) depletion studies using siRNA or genetic knockout.
• Analysis of BAX, BAK, Noxa, and Bim gene/protein expression.
• Assessment of apoptosis in MEFs (mouse embryonic fibroblasts) and HeLa cells with specific gene knockouts or downregulation.

Main Results:

• Fluorizoline-induced apoptosis is PHB-dependent; PHB-depleted cells are resistant.
• BAX and BAK are essential for fluorizoline's cytotoxic effects, confirming the intrinsic apoptosis pathway.
• Fluorizoline upregulates Noxa and Bim mRNA, but this is abrogated in PHB-depleted cells.
• Noxa/Bim deficient cells and NOXA-downregulated cells show resistance to fluorizoline.

Conclusions:

• Fluorizoline requires prohibitin proteins (PHBs) to initiate apoptosis.
• The mechanism involves the intrinsic mitochondrial apoptotic pathway, mediated by PHBs and regulated by Noxa and Bim.
• Fluorizoline represents a promising therapeutic agent targeting cancer cell apoptosis via PHB interaction.